Jun 20, 2012 by Brian Orelli, PhDGood Data. Good Enough for a Partner?Idenix provides early data on IDX184.
Jun 20, 2012 by Brian Orelli, PhDSupreme Court Obamacare Decision: What's at StakeThere are lots of potential winners and losers.
Jun 19, 2012 by Brian Orelli, PhDKiller Drug! Big Deal?Onyx's carfilzomib goes in front of an FDA advisory committee.
Jun 15, 2012 by Brian Orelli, PhDHuman Genome Goes Full MontyDisclosure is great as long as you're not embarrassed afterward.
Jun 15, 2012 by Brian Orelli, PhDIs This Improved Blockbuster Still Running Out of Time?Teva shows fewer injections of Copaxone still works.
Jun 13, 2012 by Brian Orelli, PhDCompetitor? No. Worrisome? Yes.Regeneron could be in trouble if Ophthotech's drug falls in the wrong hands.
Jun 12, 2012 by Brian Orelli, PhDHey, Look at That Data Over ThereHuman Genome makes its roundabout valuation case.
Jun 11, 2012 by Brian Orelli, PhDManagement Is Doing Its PartChelsea's management takes a pay cut to keep the lights on.
Jun 11, 2012 by Brian Orelli, PhDIf at First You Don't Succeed, Spend Millions of DollarsBioSante goes for broke trying to figure out whether LibiGel actually works.
Jun 8, 2012 by Brian Orelli, PhDNo Buyout for You. (Yet.)The depature of Achillion's CMO is a bad sign for those hoping for a buyout.
Jun 6, 2012 by Brian Orelli, PhDGunning for a Multibillion-Dollar BlockbusterAbbott's Humira gets some pressure.
Jun 5, 2012 by Brian Orelli, PhDFDA Rejection? Who CaresWhy investors shouldn't care about this FDA rejection.
Jun 1, 2012 by Brian Orelli, PhDPartner? Pretty Please?Bristol wants to hook up, but Gilead isn't interested.
May 31, 2012 by Brian Orelli, PhDNeed a Winner, Just Not at All CostsAlkermes decides not to waste money on an iffy drug.
